北科生物品牌怎么样 申请店铺

更新时间:2023-03-31
北科生物是哪个国家的品牌?「北科生物」是 深圳市北科生物科技有限公司 旗下著名品牌。该品牌发源于深圳,由创始人胡祥在2005期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
北科生物怎么样

深圳市北科生物科技有限公司(以下简称:北科生物)创建于2005年7月,是我国较早专业从事战略性新兴产业生物治疗技术临床转化及技术服务的高新技术企业。公司拥有员工400多名,其中35%以上为技术研发人员,拥有在细胞领域成果卓越的多位专家及国内外学者领衔的专业技术研发团队。

多个子公司:江苏北科、上海北科、安徽北科、辽宁北科、河南北科、贵州北科、江西北科、河北北科、北科国际(香港)、北科国际(印度)等。

全球临床研究技术支持网络:北科生物与国内外400多家科研及医疗机构开展了细胞技术相关合作,已为80000多人次难治性疾病患者的细胞治疗提供个体化细胞制备技术服务,包括来自美国、加拿大、英国、日本等70多个国家的患者,显著效果得到国际学术界的高度认可。

先进的免疫细胞治疗技术:通过战略性授权,并购和自主研发,北科在免疫治疗领域占有重要的战略地位。北科拥有多种国际先进的免疫治疗技术和产品。ALT803被NCI认为是比较有希望治愈癌症的白介素类药物。在主要组织相容性复合物抗原识别受体研发平台开发下的抗体,双特异性抗体、MCAR-T、MCAR-NK细胞治疗比目前的常规的CAR-T、TCR-T和双特异性抗体,在恶性血液病、实体瘤和病毒感染等疾病面具有更显著的治疗优势。

综合细胞库暨区域细胞制备中心国家网络:通过“铺设”一条既能满足临床需求及时性、又兼顾生产规模化的联通临床需求方和先进技术供给方的“细胞治疗高速公路网”,为细胞治疗技术临床转化提供了创新性的公共技术平台和基础设施;已先后在深圳、江苏、贵州、江西、广西、新疆建成并取得令人瞩目的成绩,为我国细胞治疗产业发展模式提供一条可借鉴的创新之路。


Founded in July 2005, Shenzhen Beike Biotechnology Co., Ltd. (hereinafter referred to as Beike Biotechnology) is an early high-tech enterprise specialized in clinical transformation and technical services of biological treatment technology in strategic emerging industries in China. The company has more than 400 employees, more than 35% of whom are technical R & D personnel. It has a number of experts with outstanding achievements in cell field and a professional R & D team led by domestic and foreign scholars. Many subsidiaries: Jiangsu Beike, Shanghai Beike, Anhui Beike, Liaoning Beike, Henan Beike, Guizhou Beike, Jiangxi Beike, Hebei Beike, Beike International (Hong Kong), Beike International (India), etc. Global clinical research technology support network: Beike biology has cooperated with more than 400 research and medical institutions at home and abroad in cell technology, and has provided individualized cell preparation technology services for cell therapy of more than 80000 patients with refractory diseases, including patients from more than 70 countries, including the United States, Canada, the United Kingdom, Japan, etc., with remarkable effects highly recognized by the international academic community Yes. Advanced immunotherapy Technology: through strategic authorization, M & A and independent research and development, Beike occupies an important strategic position in the field of immunotherapy. Beike has a variety of international advanced immunotherapy technologies and products. Alt803 is considered by NCI to be a promising interleukin drug to cure cancer. The antibody, bispecific antibody, mcar-t, mcar-nk cell therapy under the development of the main histocompatibility complex antigen recognition receptor platform has more significant therapeutic advantages than the current conventional car-t, tcr-t and bispecific antibody in the treatment of malignant hematopathy, solid tumor, virus infection and other diseases. National network of comprehensive cell bank and regional cell preparation center: through "laying" a "cell treatment expressway network" connecting clinical demand side and advanced technology supply side, which can meet clinical demand timeliness and take into account production scale, it has provided innovative public technology platform and infrastructure for clinical transformation of cell treatment technology; it has been successively in Shenzhen, Jiangsu, Jiangsu Guizhou, Jiangxi, Guangxi and Xinjiang have made remarkable achievements, which provides an innovative way for the development of cell therapy industry in China.

本文链接: https://brand.waitui.com/4357e0f5e.html 联系电话:0755-86309200

7×24h 快讯

RoboSense与上汽集团进入规模化量产合作新阶段

36氪获悉,RoboSense速腾聚创正式公布与上汽集团旗下汽车品牌飞凡汽车的定点合作。日前,双方合作的车型之一飞凡F7正式上市交付。这标志着,RoboSense速腾聚创与上汽集团的量产车型定点合作全面进入了规模化量产的新阶段。

2小时前

热门中概股美股盘前多数上涨,京东涨超5%

36氪获悉,热门中概股美股盘前多数上涨,截至发稿,京东涨超5%,拟分拆京东产发、京东工业于香港联交所主板独立上市;微博涨超3%,拼多多、蔚来、小鹏汽车、爱奇艺涨超1%,B站涨0.49%,理想汽车涨0.24%,百度跌超2%。

2小时前

贵州茅台:2022年净利润627.16亿元,同比增长19.55%

36氪获悉,贵州茅台发布年报,2022年营业收入1240.99亿元,同比增长16.87%;净利润627.16亿元,同比增长19.55%;基本每股收益49.93元。拟10派259.11元。

2小时前

天齐锂业:2022年净利润241.25亿元,同比增长1060.47%

36氪获悉,天齐锂业发布年报,2022年营业收入404.48亿元,同比增长427.82%;净利润241.24亿元,同比增长1060.47%,拟10派30元。

2小时前

亚朵集团上市后首份成绩单:2022年调整后净利润同比增85.6%至2.59亿元

亚朵集团发布2022年第四季度及全年业绩报告。2022年,亚朵集团实现营收22.63亿元,同比增长5.4%;调整后净利润(非公认会计准则)为2.59亿元,同比增长85.6%。截至2022年12月31日,亚朵集团现金及现金等价物为15.89亿元。报告期内,亚朵新开店191家,仅4家关店,在营酒店数量达932家,房间数达10.8万间,均较上年增长25%;场景零售业务增长迅猛,GMV同比增长42%至3.24亿元。

2小时前

本页详细列出关于北科生物的品牌信息,含品牌所属公司介绍,北科生物所处行业的品牌地位及优势。
咨询